Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients

200915 citationsJournal Article

Authors

Heikki Valleala · Helsinki University Hospital

Markku Korpela · Tampere University

Timo Möttönen · Turku University Hospital

Tuija Hienonen-Kempas · Roche (Finland)

Markku Kauppi

Pekka Hannonen · Central Finland Health Care District

Marjatta Leirisalo‐Repo · Helsinki University Hospital

Abstract

Rituximab can effectively control disease activity in patients with active disease and poor response to previous therapies, in combination with MTX but also with other DMARDs.

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Monoclonal and Polyclonal Antibodies Research Systemic Lupus Erythematosus Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Scandinavian Journal of Rheumatology

Volume 38, Issue 5, pp. 323-327

DOI: 10.1080/03009740902946355

Field-Weighted Citation Impact: 2.06